RECEIVE OCT 0 2 2001

PATENT APPLICATION



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TT' 1'3 (TD ATCAS (T.). 1

Hiroshi MURAKAMI et al.

Appln. No.: 09/462,740

Filed: April 5, 2000

For: TRANSGENIC MAMMALS

Confirmation No.: Unassigned

Group Art Unit: 1632

Examiner: P. PARAS JR.

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This response is in regard to the Notice to Comply issued in the above referenced patent application. While the Notice to Comply was mailed April 10, 2001, and set a one month period for response, a Petition to Reset Period for Reply Due to Late Receipt of PTO Action was filed August 30, 2001. The Petition requested that the time for reply to the Notice be reset to begin August 28, 2001. Thus, upon granting of the Petition, a reply to the Notice would be due September 28, 2001. As this response is being filed on or before September 28, 2001, it is timely.

In the Notice to Comply, the Examiner states that the present application fails to comply with the requirements of 37 C.F.R. §§1.821-1.825 because the application (1) does not contain as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37

Q57531

RESPONSE TO NOTICE TO COMPLY

C.F.R. §1.821(c), and (2) a computer readable form (CFR) of the Sequence Listing has not been submitted as required by 37 C.F.R. §1.821(e).

The Examiner further states that Applicants must provide a paper copy and a CFR copy of the Sequence Listing, and a Statement that the content of the paper and computer readable copies are the same and that they include no new matter.

In response, Applicants include herewith a paper copy and a CRF copy of the Sequencing Listing, a Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825, and a copy of the Notice to Comply.

Applicants assert that the response to the Notice to Comply and the enclosures are being timely filed, and that the enclosures bring the present application in full compliance with the requirements of 37 C.F.R. §§1.821-1.825.

Accordingly, Applicants respectfully request that the Examiner acknowledge that the Sequence Listing in the present application meets the requirements of 37 C.F.R. §§1.821-1.825.

Respectfully submitted,

Drew Hissong

Registration No. 44,765

SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC 2100 Pennsylvania Avenue, N.W. Washington, D.C. 20037-3213 Telephone: (202) 293-7060

Facsimile: (202) 293-7860

Date: September 28, 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of

Hiroshi MURAKAMI et al.

Confirmation No.: Unassigned

Appln. No.: 09/462,740

Group Art Unit: 1632

Filed: April 5, 2000

Examiner: P. PARAS JR.

For:

TRANSGENIC MAMMALS

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents Washington, D.C. 20231

Box SEQUENCE

Sir:

In connection with the 9-page Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- 1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include any new matter;
- 2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
- all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that

Q57531

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,


Drew Hissong

Registration No. 44,765

SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC 2100 Pennsylvania Avenue, N.W. Washington, D.C. 20037-3213 Telephone: (202) 293-7060

Facsimile: (202) 293-7860

Date: September 28, 2001



Application No.:09/462,740

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

X	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute

6. The paper copy of the "Sequence Listing" is not the same as the computer readable from "Sequence Listing" as required by 37 C.F.R. 1.821(e).	of the
7. Other:	

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An Initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentin Software Program Support (SIRA)

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE